- Research works
- 65 ▼ 34% vs 2013–17
- Citations
- 1.2k 18.5 per fractional work
- Top-10% rate
- 15.7% record average 16.5%
- Open access
- 45% world 28%
Not ranked overall: UCB Pharma (France) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 15.5×. Every wedge is a field page.
- Immunology and Microbiology 15.5×
- Medicine 3.7×
- Economics, Econometrics and Finance 2.7×
- Health Professions 1.2×
- Nursing 1.1×
- Neuroscience 0.4×
- Decision Sciences 0.4×
- Mathematics 0.3×
- Biochemistry, Genetics and Molecular Biology 0.3×
- Pharmacology, Toxicology and Pharmaceutics 0.2×
- Earth and Planetary Sciences 0.2×
- Psychology 0.2×
- Physics and Astronomy 0.0×
- Social Sciences 0.0×
- Engineering 0.0×
Who are the top researchers at UCB Pharma (France)?
Ranked on the composite score, Jérémy Lambert, Jean-Michel Joubert and V. Taieb lead among researchers whose main affiliation is UCB Pharma (France).
- 1 Jérémy Lambert France · #580,026 worldwide 76 citations · 15 works
- 2 Jean-Michel Joubert France · #1,467,865 worldwide 6 citations · 17 works
- 3 V. Taieb France · #1,537,128 worldwide 1 citations · 31 works
Which keywords describe research at UCB Pharma (France)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Autoantibodies, Quality of Life, Inflammation, IL-17, TH17 Cells, Ankylosing Spondylitis, Spondyloarthritis and Rheumatoid Arthritis.
- Pathogenesis
- Cost-effectiveness Analysis
- Treatment
- Acne Inversa
- Disease-Modifying Antirheumatic Drugs
- Biological Therapy
- Rheumatoid Arthritis
- Spondyloarthritis
- Ankylosing Spondylitis
- Quality of Life
- Autoantibodies
- Inflammation
- IL-17
- TH17 Cells
- Epidemiology
- Cytokines
- Immunosuppressive Therapy
- Hidradenitis Suppurativa
- Prognosis
- Health Utility Measures
- Neurological Disorders
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 21 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 21 words, with their numbers
- Autoantibodies4▲ 68×6 topics
- Quality of Life4▲ 11×4 topics
- Inflammation3▲ 7.5×7 topics
- Ankylosing Spondylitis3▲ 494×1 topic
- IL-173▲ 409×1 topic
- Spondyloarthritis3▲ 494×1 topic
- TH17 Cells3▲ 409×1 topic
- Rheumatoid Arthritis2▲ 117×2 topics
- Epidemiology2▲ 2.8×10 topics
- Biological Therapy2▲ 184×1 topic
- Cytokines2▲ 37×2 topics
- Disease-Modifying Antirheumatic Drugs2▲ 207×1 topic
- Immunosuppressive Therapy2▲ 43×3 topics
- Acne Inversa2▲ 744×1 topic
- Hidradenitis Suppurativa2▲ 744×1 topic
- Treatment2▲ 6.0×5 topics
- Prognosis2▲ 21×3 topics
- Cost-effectiveness Analysis1▲ 64×1 topic
- Health Utility Measures1▲ 64×1 topic
- Pathogenesis1▲ 10×4 topics
- Neurological Disorders1▲ 8.7×4 topics
Which research topics does UCB Pharma (France) publish most on?
By volume in 2022–2025: Spondyloarthritis Studies and Treatments, Psoriasis: Treatment and Pathogenesis, Rheumatoid Arthritis Research and Therapies and Hidradenitis Suppurativa and Treatments.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Spondyloarthritis Studies and Treatments Rheumatology 3 works
- 2 Psoriasis: Treatment and Pathogenesis Immunology 3 works
- 3 Rheumatoid Arthritis Research and Therapies Rheumatology 2 works
- 4 Hidradenitis Suppurativa and Treatments Dermatology 2 works
- 5 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 1 works
- 6 Myasthenia Gravis and Thymoma Neurology 1 works
- 7 Peripheral Neuropathies and Disorders Neurology 1 works
- 8 Fibromyalgia and Chronic Fatigue Syndrome Research Psychiatry and Mental health 0 works
- 9 Acne and Rosacea Treatments and Effects Dermatology 0 works
- 10 Coagulation, Bradykinin, Polyphosphates, and Angioedema Genetics 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has UCB Pharma (France)'s research output changed?
Output in 2018–2022 was 34% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Colombes
- Hôpital Louis-Mourier
- Arkema (France)
- Shell (France)
- Sequans Communications (France)
- Parker Hannifin (France)
- PY Automation (France)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.